GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (FRA:E4NA) » Definitions » Interest Expense

Arovella Therapeutics (FRA:E4NA) Interest Expense : €-0.01 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Arovella Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Arovella Therapeutics's interest expense for the six months ended in Jun. 2024 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.01 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Arovella Therapeutics's Operating Income for the six months ended in Jun. 2024 was € -2.99 Mil. Arovella Therapeutics's Interest Expense for the six months ended in Jun. 2024 was € 0.00 Mil. Arovella Therapeutics has no long-term debt (1). The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Arovella Therapeutics Interest Expense Historical Data

The historical data trend for Arovella Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arovella Therapeutics Interest Expense Chart

Arovella Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.02 -0.13 -0.01 -0.01

Arovella Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.02 0.01 -0.01 -

Arovella Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arovella Therapeutics  (FRA:E4NA) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Arovella Therapeutics's Interest Expense for the six months ended in Jun. 2024 was €0.00 Mil. Its Operating Income for the six months ended in Jun. 2024 was €-2.99 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2024 was €0.00 Mil.

Arovella Therapeutics's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as

Arovella Therapeutics had no long-term debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Arovella Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (FRA:E4NA) » Definitions » Interest Expense
Comparable Companies
ASX:RCE ASX:PIQ ASX:AGN ASX:EZZ ASX:PAA ASX:PAR ASX:OCC ASX:DXB ASX:RAD ASX:ACW OCSE:NOVO B REGN VRTX ASX:CSL XKRX:207940 ALNY XBRU:UCB XKRX:068270 MRNA XBRU:ARGX
Traded in Other Exchanges
ALA:Australia
Address
62 Lygon Street, Level 3, Carlton, WA, AUS, 3053
Website
https://www.arovella.com
Arovella Therapeutics Ltd is a biotechnology company focused on developing therapies to treat human diseases. Its two focus areas are oncology and conditions that impact the central nervous system. The company's principal activity is the pharmaceutical development of its invariant Natural Killer T (iNKT) cell platform for the treatment of cancer.

Arovella Therapeutics Headlines

No Headlines